4.2 Article

Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray

Journal

EXPERIMENTAL HEMATOLOGY
Volume 36, Issue 11, Pages 1471-1479

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.exphem.2008.06.006

Keywords

-

Funding

  1. NCI NIH HHS [P30 CA008748] Funding Source: Medline
  2. NHLBI NIH HHS [K08 HL082677] Funding Source: Medline

Ask authors/readers for more resources

Objective. Myeloproliferative disorders (MPD) are clonal hematopoietic diseases that include polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF). Mutations in JAK2 are present in many MPD patients. Additional genomic abnormalities are not fully examined in MPD. Materials and Methods. We used single-nucleotide polymorphism DNA microarray (SNP-chip) to analyze 43 patients with MPD (10 PV, 17 ET, and 16 PMF) for genomic aberrations. Results. Genomic abnormalities were rare in ET. The region containing either RB (13q14) or NF1 (17q11) was deleted in 4 of the 16 PMF, especially PMF with no JAK2 mutations. All five cases of PV having homozygous JAK2V617F had loss of heterozygosity with normal copy number [uniparental disomy] involving the gene. A subpopulation with 9p uniparental disomy was detected in 11 MPD (3 PV, I ET, 7 PMF). Uniparental disomy at 1p was found in one PV and three PMF. A novel mutation of MPL (Y591D), which was involved in this uniparental disomy, was found in 1 PV with JAK2 mutation. The other three cases of PMF with 1p uniparental disomy had point mutations of the MPL gene, either a novel mutation (S204F) or the previously described W515L. Conclusion. Genomic abnormalities, including 9p uniparental disomy/JAK2 point mutations, 1p uniparental disomy/MPL point mutations, deletions of RB1 and NF1 are common alterations in MPD, especially in PMF. (c) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A. Patel, Sheng F. Cai, Linde A. Miles, Robert L. Bowman, Mark B. Geyer, Andrew Dunbar, Zachary D. Epstein-Peterson, Erin McGovern, Jessica Schulman, Jacob L. Glass, Justin Taylor, Aaron D. Viny, Eytan M. Stein, Bartlomiej Getta, Maria E. Arcila, Qi Gao, Juliet Barker, Brian C. Shaffer, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Miguel-Angel Perales, Omar Abdel-Wahab, Ross L. Levine, Sergio A. Giralt, Yanming Zhang, Wenbin Xiao, Nidhi Pai, Elli Papaemmanuil, Martin S. Tallman, Mikhail Roshal, Aaron D. Goldberg

Summary: Measurable residual disease (MRD) is a powerful prognostic factor in acute myeloid leukemia (AML). This study aims to identify pre-treatment molecular predictors of immunophenotypic MRD clearance in AML patients. The results showed that induction chemotherapy led to different MRD responses, with 35% achieving MRD- remission, 27% achieving MRD+ remission, and 38% having persistent disease. Subsequent therapy resulted in MRD conversion in 34% of MRD+ patients and 26% of patients with persistent disease. Specific gene mutations and karyotypic abnormalities were found to be associated with high or low rates of MRD- remission. Patients with fewer individual clones were more likely to achieve MRD- remission. Furthermore, the study demonstrated that achieving MRD- prior to allogeneic stem cell transplant (allo-SCT) was associated with favorable outcomes. Therefore, the inclusion of patients with specific baseline mutational patterns and high clone numbers in clinical trials should be considered.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Mueller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Sator Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maclejewski, Seishi Ogawa

Summary: DDX41 gene mutations play an important role in late-onset myeloid neoplasms, but many crucial features of DDX41-mutated neoplasms still need to be elucidated. This study comprehensively characterized DDX41-mutated neoplasms and found that DDX41 risk variants accounted for 80% of known genetic predispositions to myeloid neoplasms in adults. Additionally, DDX41 risk alleles were significantly enriched in Japanese cases and more prominent in males compared to females.

BLOOD (2023)

Review Oncology

Oncogenic lesions and molecular subtypes in adults with B-cell acute lymphoblastic leukemia

Takahiko Yasuda, Masashi Sanada, Shinobu Tsuzuki, Fumihiko Hayakawa

Summary: B-cell acute lymphoblastic leukemia (B-ALL) is a genetically heterogeneous disease that can be classified into different molecular subtypes based on genetic alterations. Recent advances in sequencing technology have uncovered B-ALL molecular subtypes prevalent in adolescents and adults. These findings provide more precise prognostic estimations and personalized treatment options, as well as a deeper understanding of the genetic basis of B-ALL in these age groups.

CANCER SCIENCE (2023)

Letter Oncology

Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Kentaro Ohki, Ellie R. Butler, Nobutaka Kiyokawa, Shinsuke Hirabayashi, Anke K. Bergmann, Anja Moericke, Judith M. Boer, Helene Cave, Giovanni Cazzaniga, Allen Eng Juh Yeoh, Masashi Sanada, Toshihiko Imamura, Hiroto Inaba, Charles G. Mullighan, Mignon L. Loh, Ulrika Noren-Nystrom, Lee-Yung Shih, Marketa Zaliova, Ching-Hon Pui, Oskar A. Haas, Christine J. Harrison, Anthony V. Moorman, Atsushi Manabe

LEUKEMIA (2023)

Article Oncology

Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene

Koya Odaira, Takahiko Yasuda, Kentaro Okada, Takuya Shimooka, Yukino Kojima, Mina Noura, Shogo Tamura, Shingo Kurahashi, Eisuke Iwamoto, Masashi Sanada, Itaru Matsumura, Yasushi Miyazaki, Tetsuhito Kojima, Hitoshi Kiyoi, Shinobu Tsuzuki, Fumihiko Hayakawa

Summary: This study found that the fusion gene CEBPA-IGH suppresses the target genes of MEF2s, promoting the development of CEBPA-IGH-positive B-ALL.

CANCER SCIENCE (2023)

Article Oncology

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

Lindsay M. Gurska, Rachel Okabe, Alexandra Schurer, Meng Maxine Tong, Mark Soto, Daniel Choi, Kristina Ames, Shira Glushakow-Smith, Allison Montoya, Ellen Tein, Linde A. Miles, Haiying Cheng, Pamela Hankey-Giblin, Ross L. Levine, Swati Goel, Balazs Halmos, Kira Gritsman

Summary: The study found that crizotinib could suppress the activation of the JAK/STAT signaling pathway and decrease the disease burden of MPN. Additionally, crizotinib could overcome the persistence of JAK inhibitors by disrupting the interaction between RON kinase and JAK2. This research suggests that crizotinib should be further explored as a potential treatment for patients with MPN.

CLINICAL CANCER RESEARCH (2023)

Article Pharmacology & Pharmacy

CRISPR/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model br

Thao Thu Thi Nguyen, Yoichi Tanaka, Masashi Sanada, Masumi Hosaka, Minori Tamai, Keiko Kagami, Chiaki Komatsu, Shinpei Somazu, Daisuke Harama, Shin Kasai, Atsushi Watanabe, Koushi Akahane, Kumiko Goi, Takeshi Inukai

Summary: 6-mercaptopurine is an essential component in the maintenance therapy for childhood acute lymphoblastic leukemia. Recent sequencing analysis has identified relapse-specific mutations in the NT5C2 and PRPS1 genes, which are involved in thiopurine metabolism. The development of human leukemia models with these mutations is urgently needed to establish new therapeutic strategies for overcoming 6-mercaptopurine resistance in relapsed ALL.

MOLECULAR PHARMACOLOGY (2023)

Article Multidisciplinary Sciences

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells

Jerome Fortin, Ming-Feng Chiang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Julie Leca, Francois Lemonnier, Wanda Y. Li, Miki S. Gams, Takashi Sakamoto, Mandy Chu, Chantal Tobin, Eric Laugesen, Troy M. Robinson, Annick You-Ten, Daniel J. Butler, Thorsten Berger, Mark D. Minden, Ross L. Levine, Cynthia J. Guidos, Ari M. Melnick, Christopher E. Mason, Tak W. Maka

Summary: Mutations in IDH1, IDH2, and TET2 genes are commonly observed in myeloid neoplasms. These mutations have unexpected, distinct effects on hematopoietic stem and progenitor cells, contrary to previous expectations. Understanding these molecular alterations could lead to the development of more effective, genotype-specific therapies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Editorial Material Oncology

Oncogenic IDH1 Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types

Troy M. Robinson, Ross L. Levine

Summary: In this study, the researchers used mass spectrometry metabolomics, stable isotope labeling, and functional studies to investigate metabolic vulnerabilities in cancers with mutations in isocitrate dehydrogenase (IDH). They provide compelling evidence that dysregulated lipid synthesis is a synthetic lethal target in cancers with IDH1 mutations, but not IDH2 mutations.

CANCER DISCOVERY (2023)

Article Hematology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Andrew J. Dunbar, Dongjoo Kim, Min Lu, Mirko Farina, Robert L. Bowman, Julie L. Yang, Young Park, Abdul Karzai, Wenbin Xiao, Zach Zaroogian, Kavi O'Connor, Shoron Mowla, Francesca Gobbo, Paola Verachi, Fabrizio Martelli, Giuseppe Sarli, Lijuan Xia, Nada Elmansy, Maria Kleppe, Zhuo Chen, Yang Xiao, Erin McGovern, Jenna Snyder, Aishwarya Krishnan, Corrine Hill, Keith Cordner, Anouar Zouak, Mohamed E. Salama, Jayden Yohai, Eric Tucker, Jonathan Chen, Jing Zhou, Timothy McConnell, Anna R. Migliaccio, Richard Koche, Raajit Rampal, Rong Fan, Ross L. Levine, Ronald Hoffman

Summary: Inflammatory signaling is crucial in the development of myelofibrosis (MF), a type of cancer. Recent studies have identified the involvement of JAK/STAT and NF-kappa B signaling in MF progression. This study further explores the role of CXCL8/CXCR2 signaling in MF pathogenesis, and highlights its potential as a therapeutic target.

BLOOD (2023)

Article Oncology

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J. Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis

Summary: This study evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in patients with acute myeloid leukemia (AML) who have poor prognosis. The combination showed some activity and acceptable tolerance, but the complete remission rates were low and overall survival was short.

CANCER (2023)

Article Endocrinology & Metabolism

Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study

Laura Boucai, Ryan N. Ptashkin, Ross L. Levine, James A. Fagin

Summary: In this prospective cohort study, the effects of therapeutic radioactive iodine (RAI) on clonal hematopoiesis (CH) were examined. The results showed no increase in CH in patients treated with RAI over a 2-year follow-up period. It was also found that the presence of CH was associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.

CLINICAL ENDOCRINOLOGY (2023)

Article Multidisciplinary Sciences

MEN1 mutations mediate clinical resistance to menin inhibition

Florian Perner, Eytan M. M. Stein, Daniela V. V. Wenge, Sukrit Singh, Jeonghyeon Kim, Athina Apazidis, Homa Rahnamoun, Disha Anand, Christian Marinaccio, Charlie Hatton, Yanhe Wen, Richard M. M. Stone, David Schaller, Shoron Mowla, Wenbin Xiao, Holly A. A. Gamlen, Aaron J. J. Stonestrom, Sonali Persaud, Elizabeth Ener, Jevon A. A. Cutler, John G. G. Doench, Gerard M. M. McGeehan, Andrea Volkamer, John D. D. Chodera, Radoslaw P. Nowak, Eric S. S. Fischer, Ross L. L. Levine, Scott A. A. Armstrong, Sheng F. F. Cai

Summary: Chromatin-binding proteins are important regulators of cell state in haematopoiesis. Clinical trials have shown that the menin inhibitor revumenib can treat leukaemia with KMT2Ar or NPM1 mutations. However, acquired resistance to menin inhibition may be caused by somatic mutations in the MEN1 gene.

NATURE (2023)

Article Biochemistry & Molecular Biology

Clonal hematopoiesis, aging and Alzheimer's disease

Pablo Sanchez Vela, Jennifer J. J. Trowbridge, Ross L. L. Levine

Summary: New data reveals the surprising association between clonal hematopoiesis and protection from Alzheimer's disease, highlighting the need for future studies to unravel the complex mechanisms underlying the role of clonal hematopoiesis in tissue-disease contexts and aging-associated diseases.

NATURE MEDICINE (2023)

Article Hematology

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-Bartnicka, Kumaraswamy N. Chitrala, Jessica Atkins, Malgorzata Drzewiecka, Wanjuan Feng, Joe Chan, Srinivas Chatla, Konstantin Golovine, Jaroslav Jelinek, Tomasz Sliwinski, Jayashri Ghosh, Ksenia Matlawska-Wasowska, Gurushankar Chandramouly, Reza Nejati, Mariusz Wasik, Stephen M. Sykes, Katarzyna Piwocka, Emir Hadzijusufovic, Peter Valent, Richard T. Pomerantz, George Morton, Wayne Childers, Huaqing Zhao, Elisabeth M. Paietta, Ross L. Levine, Martin S. Tallman, Hugo F. Fernandez, Mark R. Litzow, Gaorav P. Gupta, Jean-Yves Masson, Tomasz Skorski

Summary: Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. Formaldehyde generated by serine/1-carbon cycle metabolism contributes to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells. Oncogenic tyrosine kinases (OTKs) enhance the expression of DNA polymerase theta (POL theta) to repair DPC-containing DNA double-strand breaks. Inhibition of POL theta can be an effective therapeutic strategy for leukemia.

BLOOD (2023)

No Data Available